Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Opmed

Explore full profile

Automates resource planning and allocation process to be resilient and optimized

Ramat Gan, IsraelFounded 2020Biotech & Life Sciences
Valuation $50–100M Last recorded · 2024
Revenue <$1M Latest reported FY
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Opmed and the history behind them.

About Opmed

Opmed.ai offers an AI-powered optimization platform tailored for the healthcare sector, with a specific focus on enhancing the operational efficiency of hospitals and other healthcare facilities. The company's core product is a sophisticated engine that leverages artificial intelligence and network science to address complex scheduling and resource allocation challenges. Initially targeting operating rooms (OR), the system optimizes scheduling to maximize utilization, reduce patient wait times, and improve overall throughput.

The platform's capabilities extend beyond the OR to other critical areas such as inpatient care, cath labs, and rehabilitation centers. By analyzing vast amounts of data, the system provides real-time, data-driven insights that empower hospital administrators to make informed decisions. It can predict demand, balance patient loads across different units, and optimize staff schedules, including those for nurses, based on real-time operational data. This approach helps to alleviate bottlenecks, prevent staff burnout, and ensure that resources are allocated where they are most needed.

The business model appears to be B2B, selling its SaaS solution directly to healthcare providers, including large hospital systems like Geisinger. The company generates revenue by licensing its platform. By demonstrating a clear return on investment through cost savings, increased revenue from higher patient throughput, and improved patient outcomes, Opmed.ai positions itself as a critical tool for modern healthcare management.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2020
Headquarters
Ramat Gan, Israel
Employees
62
Open positions
3
Dealroom signal
86.7/100
Industry
Health
Sub-industry
BioTechnology, Health Platform
Sector
Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
SaaS
Client focus
b2b

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC May 2024 $15M $60M Secret Chord Ventures · Sir Ronald Cohen · Grove Ventures · Operator Partners ↗
SPINOUT✓Other financing Jan 2020 $0 — Bar-Ilan University —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowth
2026
2025
2024
2023
2022
2021 —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Opmed website traffic

Latest recorded traffic for Opmed is 3.8K monthly website visits, down 19.1% over the last three months. Opmed's team grew 10.7% over the past year.

Latest monthly visits3.8K 3-month web change-19.1% 1-year team growth+10.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A10 investors entered at this stage

  • Grove Ventures
  • NFX
  • Secret Chord Ventures
  • Sir Ronald Cohen
  • Operator Partners
  • Launch It Capital
  • Danielle Yanai
  • Guy Schory
  • Simon Legziel
  • unbox ventures

Other known investors1 additional known investor

  • Bar-Ilan University
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States37.7%
🇮🇱 Israel30.2%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Opmed on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Opmed’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.